IP Library Granted Patent US 6,998,105
Granted Patent B2
US 6,998,105 · App. 10/173,497 · Granted Feb 14, 2006

Low density radionuclide-containing particulate material

Assignee: Sirtex Medical Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,998,105
App. No.
10/173,497
Granted
Feb 14, 2006
Kind
B2
Abstract

The invention relates to a particulate material consisting of a low density radiation-tolerant glass and a radionuclide incorporated into the low density glass or coated on the low density glass, the glass having a density of less than 2.5 g/cm 3 , processes for its production and a method of radiation therapy utilising the patentable material.

Claims (20)

1. A particulate material comprising a low density radiation-tolerant glass and one or two radionuclides incorporated into the low density glass, the glass having a density of less than 2.5 g/cm 3 , wherein the radionuclide is an isotope selected from the group consisting of holmium, samarium, iodine, iridium, rhenium, and yttrium, and wherein the low density glass comprises SiO 2 and B 2 O 3 , and the weight percentage of [SiO 2 +B 2 O 3 ] in the glass is at least 70%.

2. The particulate material according to claim 1 , wherein the density of the glass is less than 2.4 g/cm 3 .

3. The particulate material according to claim 1 , wherein low density glass comprises from 95% to 100% SiO 2 .

4. The particulate material according to claim 1 , wherein the weight percentage of [SiO 2 +B 2 O 3 ] in the glass is at least 80%.

5. The particulate material according to claim 1 , wherein the SiO 2 content of the glass is at least 60% by weight, and the B 2 O 3 content is at least 10% by weight.

6. The particulate material according to claim 1 , wherein the composition of the glass is 72% SiO 2 , 25% B 2 O 3 , 1% Al 2 O 3 , 0.5% Li 2 O 0.5% Na 2 O and 1% K 2 O.

7. The particulate material according to claim 1 , which is a microsphere having a diameter in the range of from 5 to 200 microns.

8. The particulate material according to claim 7 , wherein the diameter is in the range of from 15 to 100 microns.

9. The particulate material according to claim 1 , wherein the radionuclide is yttrium-90.

10. A process for the production of a particulate material according to claim 1 comprising melting together a low density radiation-tolerant glass and a radionuclide or radionuclide precursor and solidifying the melt to produce a particulate material, and then if necessary activating the precursor to form the radionuclide.

11. The process according to claim 10 , wherein the radionuclide is yttrium-90.

12. A method of radiation therapy of a patient, which comprises administration to the patient of a particulate material according to claim 1 .

13. The method according to claim 12 , wherein the radionuclide is yttrium-90.

14. The method according to claim 12 , wherein the radiation therapy comprises treatment of a primary or secondary liver cancer.

15. The particulate material according to claim 1 , wherein the density of the glass is less than 2.3 g/cm 3 .

16. The particulate material according to claim 1 , wherein the density of the glass is less than 2.2 g/cm 3 .

17. The particulate material according to claim 1 , wherein the weight percentage of [SiO 2 +B2O 3 ] in the glass is at least 85%.

18. The particulate material according to claim 1 , wherein the weight percentage of [SiO 2 +B2O 3 ] in the glass is at least 90%.

19. The particulate material according to claim 7 , wherein the diameter is in the range of from 20 to 50 microns.

20. The particulate material according to claim 7 , wherein the diameter is in the range of from 30 to 35 microns.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2024
From: CHINA CITIC BANK INTERNATIONAL LIMITED
To: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
Reel/Frame 067944/0310 →
SECURITY INTEREST Recorded Jun 16, 2022
From: GRAND PHARMA SPHERE (AUSTRALIA BIDCO) PTY LTD; SIRTEX MEDICAL PTY LTD; SIRTEX MEDICAL PRODUCTS PTY LTD; SIRTEX GLOBAL PTY LTD; SIRTEX TECHNOLOGY PTY LTD
To: CHINA CITIC BANK INTERNATIONAL LIMITED
Reel/Frame 060450/0744 →
SECURITY INTEREST Recorded Nov 30, 2018
From: SIRTEX MEDICAL LIMITED
To: BANK OF CHINA LIMITED MACAU BRANCH
Reel/Frame 047691/0520 →
ASSIGNEE ADDRESS CHANGES Recorded Aug 1, 2005
From: SIRTEX MEDICAL LIMITED
To: SIRTEX MEDICAL LIMITED
Reel/Frame 016882/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2002
From: RUYS, ANDREW JOHN; GRAY, BRUCE NATHANIEL
To: SIRTEX MEDICAL LIMITED
Reel/Frame 013171/0601 →
Priority Claims (1)
AU PR0982 · Oct 25, 2000 · national
Continuity (2)
Continuation PCTAU010136900 · Oct 25, 2001
Related Publication 20020197208A1 · Dec 26, 2002